Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Screen on your Watchlists and Portfolios with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Nephrogenex Inc (NRX)

Nephrogenex Inc (NRX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,680
  • Shares Outstanding, K 12,950
  • Annual Sales, $ 0 K
  • Annual Income, $ -22,860 K
  • 60-Month Beta 0.57
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 0.16
Trade NRX with:
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -1.25
  • Most Recent Earnings N/A on N/A
  • Next Earnings Date 05/11/16
  • Annual Dividend & Yield 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.10 +40.00%
on 05/09/16
0.88 -84.09%
on 04/26/16
-0.33 (-70.21%)
since 04/08/16
3-Month
0.10 +40.00%
on 05/09/16
1.20 -88.33%
on 02/22/16
-0.81 (-85.26%)
since 02/10/16
52-Week
0.10 +40.00%
on 05/09/16
8.90 -98.43%
on 06/23/15
-7.28 (-98.11%)
since 05/08/15

Most Recent Stories

More News
Orphan Drugs Worth $64 Billion by 2028 and This Micro Cap Could Have One by That Time

There are very good reasons that stocks generally gain in value after a company receives %OrphanDrug designation (ODD). A study published in Orphanet Journal of Rare Diseases showed that the average stock...

SNY : 50.40 (+0.38%)
TAK : 13.51 (-1.39%)
NRX.VN : 0.730 (+5.80%)
BMY : 43.50 (+0.81%)
NRX : 0.14 (+7.69%)
When Technicals and Fundamentals Converge, A Nice Uptrend Ensues

Some investors only pay attention to fundamentals. Others put more weight on technical charts. Another way of looking at it is to think of technical as being useful for quick decisions for those good at...

RIO : 64.73 (-1.58%)
NRDS : 15.19 (-1.30%)
NOA.TO : 27.01 (-0.37%)
NRX.VN : 0.730 (+5.80%)
NOA : 19.72 (-0.55%)
NRX : 0.14 (+7.69%)
24 Cent Micro Cap May Hold The Key To Potential Breakthrough In Acute Spinal Cord Injury

An estimated 250,000-500,000 people experience a %SpinalCordInjury (SCI) annually, with roughly 17,000 new cases in the US and 27,000 in Europe each year, leaving many of those people permanently confined...

TECH : 76.61 (-2.15%)
LLY : 852.60 (-5.85%)
CAPR : 4.69 (-2.70%)
NRX.VN : 0.730 (+5.80%)
NRX : 0.14 (+7.69%)
PARS : 0.0200 (-48.72%)
White Metal Partner Noronex Commences 10,000 Metre Drilling Program at the DorWit Copper-Silver Project, Namibia

THUNDER BAY, Ontario, Sept. 09, 2021 (GLOBE NEWSWIRE) -- White Metal Resources Corp. (TSXV: WHM) (FRA: CGK1) (OTCMKTS: TNMLF) (“White Metal” or the “Company”) is pleased to provide an update...

NRX.AX : 0.015 (+15.38%)
WHM.VN : 0.060 (+9.09%)
TNMLF : 0.0408 (-0.49%)
NRX : 0.14 (+7.69%)
White Metal Partner Noronex Provides Update on Exploration Program at the DorWit Copper-Silver Project, Namibia

THUNDER BAY, Ontario, July 20, 2021 (GLOBE NEWSWIRE) -- White Metal Resources Corp. (TSXV: WHM) ( FRA: CGK1 ) ( OTCMKTS: TNMLF) (“White Metal” or the “Company”) is pleased to provide an update...

TNMLF : 0.0408 (-0.49%)
WHM.VN : 0.060 (+9.09%)
NRX : 0.14 (+7.69%)
Aquestive Therapeutics Strengthens Board of Directors with Appointments of Julie Krop, M.D., and Marco Taglietti, M.D., and Announces Resignation of Douglas K. Bratton from Board of Directors

WARREN, N.J., Feb. 09, 2021 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST), a pharmaceutical company focused on developing and commercializing differentiated products that address patients’...

AQST : 3.09 (-0.32%)
FRLN : 6.48 (unch)
AMAG : 13.75 (+0.15%)
VRTX : 489.46 (+0.22%)
SYK : 331.92 (-0.81%)
SCYX : 2.10 (-3.23%)
ABBV : 173.94 (-0.76%)
DCTH : 7.49 (-4.22%)
NRX : 0.14 (+7.69%)

Business Summary

NephroGenex, Inc. is a pharmaceutical company focused on the development of therapeutics to treat kidney disease. It is developing a small molecule drug that acts as an inhibitor of the pathogenic oxidative chemistries which are elevated in diabetic patients. NephroGenex, Inc. is based in United States....

See More

Key Turning Points

3rd Resistance Point N/A
2nd Resistance Point 0.18
1st Resistance Point 0.16
Last Price 0.14
1st Support Level 0.12
2nd Support Level 0.10
3rd Support Level N/A

See More

52-Week High 8.90
Fibonacci 61.8% 5.54
Fibonacci 50% 4.50
Fibonacci 38.2% 3.46
Last Price 0.14
52-Week Low 0.10

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar